The CHD2 (Chromodomain Helicase DNA-binding protein 2) antibody is a tool used to detect and study the CHD2 protein, a member of the CHD family of ATP-dependent chromatin remodelers. CHD2 plays a critical role in regulating gene expression by modifying chromatin structure, facilitating DNA accessibility for transcription, replication, and repair. It is involved in neurodevelopment, synaptic plasticity, and cellular differentiation. Mutations in the CHD2 gene are linked to neurodevelopmental disorders, including epilepsy (e.g., Dravet-like syndromes), autism spectrum disorders, and intellectual disabilities. Researchers use CHD2 antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to analyze protein expression, localization, and interactions in tissues or cultured cells. These studies help elucidate CHD2’s role in disease mechanisms and normal cellular processes. Commercially available antibodies are typically validated for specificity using knockout controls or siRNA-based approaches. However, variability in antibody performance across experimental conditions requires careful optimization. CHD2 research contributes to understanding epigenetic regulation and identifying therapeutic targets for neurological and developmental disorders associated with its dysfunction.